scholarly journals Quantitative imaging biomarkers: A review of statistical methods for technical performance assessment

2014 ◽  
Vol 24 (1) ◽  
pp. 27-67 ◽  
Author(s):  
David L Raunig ◽  
Lisa M McShane ◽  
Gene Pennello ◽  
Constantine Gatsonis ◽  
Paul L Carson ◽  
...  
2017 ◽  
Vol 27 (10) ◽  
pp. 3139-3150 ◽  
Author(s):  
Nancy A Obuchowski ◽  
Jennifer Bullen

Introduction Quantitative imaging biomarkers (QIBs) are being increasingly used in medical practice and clinical trials. An essential first step in the adoption of a quantitative imaging biomarker is the characterization of its technical performance, i.e. precision and bias, through one or more performance studies. Then, given the technical performance, a confidence interval for a new patient’s true biomarker value can be constructed. Estimating bias and precision can be problematic because rarely are both estimated in the same study, precision studies are usually quite small, and bias cannot be measured when there is no reference standard. Methods A Monte Carlo simulation study was conducted to assess factors affecting nominal coverage of confidence intervals for a new patient’s quantitative imaging biomarker measurement and for change in the quantitative imaging biomarker over time. Factors considered include sample size for estimating bias and precision, effect of fixed and non-proportional bias, clustered data, and absence of a reference standard. Results Technical performance studies of a quantitative imaging biomarker should include at least 35 test–retest subjects to estimate precision and 65 cases to estimate bias. Confidence intervals for a new patient’s quantitative imaging biomarker measurement constructed under the no-bias assumption provide nominal coverage as long as the fixed bias is <12%. For confidence intervals of the true change over time, linearity must hold and the slope of the regression of the measurements vs. true values should be between 0.95 and 1.05. The regression slope can be assessed adequately as long as fixed multiples of the measurand can be generated. Even small non-proportional bias greatly reduces confidence interval coverage. Multiple lesions in the same subject can be treated as independent when estimating precision. Conclusion Technical performance studies of quantitative imaging biomarkers require moderate sample sizes in order to provide robust estimates of bias and precision for constructing confidence intervals for new patients. Assumptions of linearity and non-proportional bias should be assessed thoroughly.


2014 ◽  
Vol 24 (1) ◽  
pp. 68-106 ◽  
Author(s):  
Nancy A Obuchowski ◽  
Anthony P Reeves ◽  
Erich P Huang ◽  
Xiao-Feng Wang ◽  
Andrew J Buckler ◽  
...  

2021 ◽  
pp. 174077452098193
Author(s):  
Nancy A Obuchowski ◽  
Erick M Remer ◽  
Ken Sakaie ◽  
Erika Schneider ◽  
Robert J Fox ◽  
...  

Background/aims Quantitative imaging biomarkers have the potential to detect change in disease early and noninvasively, providing information about the diagnosis and prognosis of a patient, aiding in monitoring disease, and informing when therapy is effective. In clinical trials testing new therapies, there has been a tendency to ignore the variability and bias in quantitative imaging biomarker measurements. Unfortunately, this can lead to underpowered studies and incorrect estimates of the treatment effect. We illustrate the problem when non-constant measurement bias is ignored and show how treatment effect estimates can be corrected. Methods Monte Carlo simulation was used to assess the coverage of 95% confidence intervals for the treatment effect when non-constant bias is ignored versus when the bias is corrected for. Three examples are presented to illustrate the methods: doubling times of lung nodules, rates of change in brain atrophy in progressive multiple sclerosis clinical trials, and changes in proton-density fat fraction in trials for patients with nonalcoholic fatty liver disease. Results Incorrectly assuming that the measurement bias is constant leads to 95% confidence intervals for the treatment effect with reduced coverage (<95%); the coverage is especially reduced when the quantitative imaging biomarker measurements have good precision and/or there is a large treatment effect. Estimates of the measurement bias from technical performance validation studies can be used to correct the confidence intervals for the treatment effect. Conclusion Technical performance validation studies of quantitative imaging biomarkers are needed to supplement clinical trial data to provide unbiased estimates of the treatment effect.


RSC Advances ◽  
2016 ◽  
Vol 6 (48) ◽  
pp. 42612-42612
Author(s):  
Satarupa Banerjee ◽  
Swarnadip Chatterjee ◽  
Anji Anura ◽  
Jitamanyu Chakrabarty ◽  
Mousumi Pal ◽  
...  

Correction for ‘Global spectral and local molecular connects for optical coherence tomography features to classify oral lesions towards unravelling quantitative imaging biomarkers’ by Satarupa Banerjee et al., RSC Adv., 2016, 6, 7511–7520.


2019 ◽  
Vol 60 (8) ◽  
pp. 1066-1072
Author(s):  
Isabel Schobert ◽  
Julius Chapiro ◽  
Nariman Nezami ◽  
Charlie A. Hamm ◽  
Bernhard Gebauer ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document